Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...
More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival's ...
Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...
Novo Nordisk’s next-gen medication is called CagriSema. It’s a once-weekly shot that combines a long-acting amylin analogue ...
Novo Nordisk's (DK:NOVO.B) next-gen medication is called CagriSema. It's a once-weekly shot that combines a long-acting amylin analogue and Wegovy. Clinical trials found that patients taking CagriSema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback